Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents

by Matthijs A. Velders, Sjoerd H. Hofma, Jan Brouwer, Cornelis Jan de Vries, Michel Queré, Adrianus J. van Boven
Published 2013-01-01

Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents.

by Matthijs A Velders, Sjoerd H Hofma, Jan Brouwer, Cornelis Jan de Vries, Michel Queré, Adrianus J van Boven
Published 2014-01-01

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents.

by Matthijs A. Velders, Sjoerd H. Hofma, Jan Brouwer, Cornelis Jan de Vries, Michel Queré, Adrianus J. van Boven
Published 2013-01-01

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry

by A. Selvarajah, A. H. Tavenier, W. L. Bor, V. Houben, S. Rasoul, E. Kaplan, K. Teeuwen, S. H. Hofma, E. Lipsic, G. Amoroso, M. A. H. van Leeuwen, J. M. ten Berg, A. W. J. van ‘t Hof, R. S. Hermanides
Published 2021-06-01